Related Experiment Videos

The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?

Muthusamy Kunnimalaiyaan1, Herbert Chen

  • 1Department of Surgery, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA.

Anti-Cancer Drugs
|January 24, 2006
PubMed

Insights

Activating the Ras/Raf pathway, specifically Raf-1, inhibited neuroendocrine tumor growth and reduced key markers. This suggests Raf-1 activators are promising for treating specific neuroendocrine tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Neuroendocrine (NE) tumors are metastatic and secrete biogenic amines and hormones.
  • Current therapeutic strategies for NE tumors are limited, necessitating novel treatment approaches.

Purpose of the Study:

  • To investigate the therapeutic potential of activating the Ras/Raf signaling pathway in select NE tumors.
  • To evaluate the effect of Raf-1 activation on NE tumor growth and marker secretion.

Main Methods:

  • In-vitro activation of Raf-1 in NE tumor cells using ectopic catalytic domain expression or the drug ZM336372.
  • Assessment of tumor growth inhibition and reduction in NE markers (serotonin, chromogranin A, calcitonin).

Main Results:

  • In-vitro activation of Raf-1 resulted in significant growth inhibition of NE tumor cells.
  • Activation of the Ras/Raf pathway led to a marked reduction in NE markers, including serotonin, chromogranin A, and calcitonin.

Conclusions:

  • Activation of the Ras/Raf pathway, particularly Raf-1, demonstrates therapeutic potential for NE tumors.
  • Raf-1-activating compounds warrant further development for treating specific subtypes of NE tumors.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...